Developer docs
API playgroundTry for free, no card

Search company profiles

Prolytix

Full company profile

uuid000c9fp

Namestring
Prolytix
Legal namestring
Haematologic Technologies, LLC
Websiteurl
goprolytix.com
Company typeenum
Private
Founded yearint
1987
Descriptiontext

Prolytix is a privately held, U.S.-based bioanalytical Contract Research Organization (CRO) operating from Essex Junction, Vermont, focused exclusively on large molecule (biologics) drug development. Founded in 1987 as Haematologic Technologies by thrombosis and hemostasis scientist Kenneth Mann and rebranded to Prolytix in March 2022, the company provides assay development, validation, and release testing across protein therapeutics, coagulation and hematology therapies, plasma-derived products, and cell/gene therapies, operating in integrated GLP, GCP, CLIA, and GMP facilities certified to ISO 9001:2015. Its service portfolio spans PK/PD assays, immunogenicity (anti-drug antibody) testing, biomarker assays, GMP stability and release testing, host cell protein analysis using both ELISA and high-resolution mass spectrometry, and bioanalytical support for monoclonal antibodies, bispecifics, recombinant proteins, vaccines, and viral vectors.

The company monetizes primarily through statement-of-work-based CRO services billed at quoted per-project and hourly out-of-scope rates (Net 30 terms), supplemented by product revenue from a research-reagent catalog of 150+ blood coagulation products (plasma proteins, antibodies, deficient plasmas, custom IVD/POC reagents) and Custom Collection Devices (custom-formulated blood collection tubes) developed jointly with Greiner Bio-One. Reagent products are sold direct via the company's e-commerce storefront with bill-and-hold terms, while services engage via high-touch enterprise field sales with senior scientific staff embedded in client collaboration. Proprietary assets include the PROPath real-time project tracker, a mixed-mode HPLC method for polysorbate detection, a novel plasma fractionation technique for IgG, HRMS-based HCP workflows, and 60 validated thrombosis and hemostasis assays acquired from the Hemostasis Reference Laboratory in January 2026. The company sells primarily to biotech and biopharma developers of large molecule therapeutics, with >90% of new clients signing for a second project and 100% on-time delivery cited as core differentiators versus larger global CROs. Distribution and customer engagement are direct (phone, contact form, conference booths at ISTH/AAPS/ADLM/PPTA) with no channel partners or resellers.

The company has been PE-controlled since October 2019 under Edgewater Capital Partners, a Cleveland-based lower middle-market private equity firm focused on performance materials and life sciences. Governance includes CEO David Sunseri, Ph.D., COO Ryan Dorfman, Ph.D., and CFO Robert Weisman, with strategy centered on scaling the biologics CRO platform via organic capability expansion, bolt-on acquisitions (e.g., the HRL assay purchase, the Allumiqs multiomics partnership of March 2024), and entry into adjacent modalities such as cell and gene therapy and AI model validation.

Short descriptiontext

Prolytix is a U.S.-based, PE-owned bioanalytical CRO providing GLP/GCP/CLIA/GMP-compliant assay development, validation, and release testing for biotech and biopharma companies developing large molecule therapeutics, coagulation/hematology products, plasma-derived therapies, and cell/gene therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEssex Junction, United States
HQ citystring
Essex Junction
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioanalytical testing services, contract research organization, protein characterization services, GMP release testing, host cell protein analysis
Industry3 codes
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Bioanalytical Contract Research Services for Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1Bioanalytical CRO Services (Contract Research)
TypeProfessional Services
Description

Fee-for-service contract research organized by statement of work, quoted per project, billed at hourly rates for work outside standard scope. Services span GLP/GCP/CLIA/GMP assay development, validation, stability testing, release testing, and bioanalytical testing. Represents the core revenue stream.

goprolytix.com
2GMP Stability Testing & Storage
TypeProfessional Services
Description

GMP-compliant stability testing and storage services for drug substance and drug product, supporting ICH-compliant programs and shelf-life determination.

goprolytix.com
3GMP Release Testing
TypeProfessional Services
Description

GMP release testing for bulk, final product, and in-process materials with pre-defined release protocols.

goprolytix.com
4Research Reagent and Custom Product Sales
TypeHardware Sales
Description

Sale of high-quality research reagents (plasma proteins, antibodies, inhibitors, substrates, deficient plasmas), custom IVD/POC reagents, and customized blood collection tubes. Subject to bill-and-hold arrangements. Courier expenses invoiced as pass-through plus 15%.

goprolytix.com
5Custom Collection Devices
TypeHardware Sales
Description

Custom-designed and manufactured blood collection tubes and sample preservation devices for clinical trials and novel diagnostics, available in small pilot batches through large-scale GMP production.

goprolytix.com
6Critical Reagent Manufacturing
TypeHardware Sales
Description

Manufacturing of custom critical reagents for biotherapeutic development programs.

goprolytix.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details3 tiers
1Project-Based Quoting (CRO Services)
ModelOtherBilling cadenceMulti-year contract
Notes

CRO services priced per project via statement of work quotation. Hourly rates apply for out-of-scope work including third-party communications, design/specification modifications, additional report copies, and out-of-hours work.

goprolytix.com
2Bill-and-Hold for Manufactured Materials
ModelOtherBilling cadencePay-as-you-go
Notes

Manufactured materials (reagents, collection devices) are subject to bill-and-hold arrangements where products are ready but client requests delayed delivery.

goprolytix.com
3Net 30 Payment Terms
ModelOtherBilling cadenceMonthly
Notes

Net 30 days upon receipt of invoice for all products and services. Prices exclude taxes, duties, levies, delivery, and handling charges (gel packs, dry ice as needed).

goprolytix.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1PROPath
Description

Real-time project tracker software for project management

goprolytix.com
+1 more record
Core offering1 text field

Prolytix is a bioanalytical Contract Research Organization that provides GLP, GCP, CLIA, and GMP compliant assay development, validation, stability testing, and release testing services for large molecule therapeutics including monoclonal antibodies, bispecifics, recombinant proteins, plasma-derived therapies, gene therapies, and vaccines. The company also manufactures and sells custom blood collection devices, critical reagents, and high-quality research reagents for biotech and biopharma clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >90% of new clients sign for a second bioanalytical services project
+3 more records
Product overview1 text field

Prolytix is a bioanalytical Contract Research Organization (CRO) offering integrated services for large molecule biotherapeutic development. The portfolio includes drug modality-focused bioanalytical services (Coagulation & Hematology, Protein Based Therapeutics, Plasma-Derived Therapies, Food Allergens), regulatory-compliant testing services (GLP/GCP/CLIA/GMP), characterization and development services, proprietary PROPath project tracking software, and research reagent products. Solutions span Cell and Gene Therapies, Monoclonal & Polyclonal Antibodies, Vaccines and Viral Vectors, Recombinant Proteins, and Plasma-Based Proteins. Custom Collection Devices and Critical Reagent Manufacturing support clinical trials and diagnostic development. The company operates from 57 River Road in Essex Junction, VT, with over 35 years of protein chemistry expertise.

Product and service11 records
1Coagulation & Hematology Bioanalytical Services
CategoryBioanalytical CRO Services
Description

Comprehensive bioanalytical testing services for hemophilia A and B, hemophilia C (Factor XI deficiency), von Willebrand Disease, direct oral anti-coagulants (DOACs), thrombin generation assays, platelet aggregation, and hemostatic risk evaluation for plasma-derived products, designed for biotech and biopharma developers of coagulation and hematology therapeutics.

2Protein-Based Therapeutics Bioanalytical Services
CategoryBioanalytical CRO Services
Description

Bioanalytical assay development and validation services for monoclonal antibodies, bi- and tri-specific proteins, recombinant proteins, enzyme replacement therapies, and biosimilars, supporting biotech and biopharma developers of large molecule protein therapeutics from discovery through commercialization.

3Plasma-Derived Therapies Bioanalytical Services
CategoryBioanalytical CRO Services
Description

Bioanalytical services for plasma fractionation and biotherapeutic development, including IVIG therapeutics, clotting factor analysis, and plasma protein characterization for plasma-derived therapy developers.

4GLP, GCP & CLIA Services
CategoryRegulatory-Compliant Testing Services
Description

Regulatory-compliant bioanalytical testing services delivered under GLP, GCP, and CLIA frameworks, including pharmacokinetics assays, immunogenicity (anti-drug antibody) assays, biomarker assays, and hemostasis and coagulation assays and platforms.

5GMP Services (Stability Testing & Release Testing)
CategoryRegulatory-Compliant Testing Services
Description

GMP-compliant stability testing and storage and release testing for bulk, final product, and in-process materials, supporting ICH-compliant programs and shelf-life determination for large molecule biopharmaceuticals.

6Characterization & Development Services
CategoryBioanalytical CRO Services
Description

Method development, process development, protein characterization, and host cell protein analysis services for biotherapeutic development, leveraging high-resolution mass spectrometry (HRMS) alongside ELISA for comprehensive HCP identification and risk assessment.

7PROPath Real-Time Project Tracker
CategoryProprietary Project Management Software
Description

Proprietary real-time project management software that provides clients transparent access to project milestones, enabling faster decision-making and supporting highly effective program management with on-time delivery.

8Analytical Validation of AI Models
CategoryBioanalytical CRO Services
Description

Service offering for analytical validation of AI models, bridging in silico predictions with empirical laboratory data for AI-driven biotech companies developing large molecule therapeutics.

9Custom Collection Devices (CCD)
CategoryCustom Manufactured Products
Description

Custom-designed and manufactured blood collection tubes and sample preservation devices for clinical trials and novel diagnostics, available in small pilot batches through large-scale GMP production via partnership with Greiner Bio-One.

10Critical Reagent Manufacturing
CategoryCustom Manufactured Products
Description

Manufacturing of custom critical reagents, including plasma proteins, antibodies, and custom IVD/POC device reagents for research and diagnostic applications.

11High-Quality Research Reagents (Shop Products)
CategoryResearch Reagent Products
Description

Off-the-shelf and custom research reagents including coagulation proteins, antibodies, inhibitors, substrates, deficient plasmas, and custom IVD/POC reagents, sold directly through the Prolytix website storefront.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-11
Description

Long-term strategic partnership focused on delivering integrated solutions to help customers optimize drug development pipelines. Allumiqs brings multiomics and LC-MS/MS expertise in early R&D phases (mechanism of action, biomarker identification, drug product characteristics), while Prolytix provides complementary targeted method development for stability, potency, and GMP release testing. Together they offer interconnected solutions and blended expert teams, reducing risks and complications of transferring R&D work between vendors. The partnership was formalized after several successful joint customer engagements.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-20
Description

Collaboration to provide end-to-end development and custom manufacturing of blood collection tubes for IVD and clinical diagnostic device developers. HTI (now Prolytix) contributes pilot-scale and small-to-medium batch customized blood collection tube production, while Greiner Bio-One contributes GMP-level high-volume batch manufacturing. The partnership creates a vertically integrated solution spanning early development to large-scale commercial production, enabling IVD developers to engage a single group rather than multiple vendors. HTI has sourced empty tubes and caps from Greiner Bio-One for many years prior to the formal collaboration.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioAgilytix is a bioanalytical CRO specializing in large molecule biologics, immunoassays (PK, ADA, biomarker), and cell-based assays for biotech and pharma. Most directly comparable to Prolytix by therapeutic focus, assay types, and customer segment.

TypeDirect peer
Description

KCAS is a bioanalytical CRO focused on large molecule bioanalysis using LC-MS/MS, immunoassays, and biomarker services for biopharmaceutical clients. Similar size and modality mix, with overlapping capabilities in protein therapeutic characterization.

TypeDirect peer
Description

Celerion is a clinical bioanalytical and early-phase CRO offering bioanalytical assay development, validation, and sample analysis for small and large molecules. Overlaps with Prolytix on regulated bioanalytical services for biopharma.

TypeDirect peer
Description

Frontage provides bioanalytical, CMC, and clinical laboratory services to biopharmaceutical companies, with significant large molecule bioanalysis and GMP release testing capabilities directly comparable to Prolytix's service portfolio.

TypeDirect peer
Description

Worldwide Clinical Trials is a mid-sized CRO providing bioanalytical and clinical pharmacology services with strong capabilities in immunoassay and LC-MS/MS bioanalysis for biologics and complex therapeutics. Comparable in scale and scientific depth.

TypeBroad incumbent
Description

Charles River is a global, publicly-traded CRO offering bioanalytical, safety, and manufacturing services including large molecule and biologics support. Significantly larger than Prolytix and serves the same biotech/biopharma customer base with broader portfolio.

TypeBroad incumbent
Description

Labcorp (including the former Covance) operates one of the largest global CRO and central lab networks, providing bioanalytical, biomarker, and clinical trial lab services. Competes with Prolytix for large molecule bioanalytical contracts from pharma/biotech.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO with extensive bioanalytical laboratory capabilities supporting biologics and complex therapeutic development. Competes with Prolytix at the high end of large molecule bioanalytical services.

TypeBroad incumbent
Description

Eurofins operates a global network of bioanalytical and pharmaceutical testing laboratories, including specialty large molecule and biologics testing services. Overlaps with Prolytix across protein characterization, HCP, and release testing.

TypeBroad incumbent
Description

Thermo Fisher's PPD clinical research business provides global bioanalytical and biologics testing services as part of its integrated CRO offering. Comparable to Prolytix in large molecule bioanalysis but operates at materially greater scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prolytix

Bioanalytical Contract Research Services for Biopharmaceuticalsgoprolytix.com

Prolytix is a U.S.-based, PE-owned bioanalytical CRO providing GLP/GCP/CLIA/GMP-compliant assay development, validation, and release testing for biotech and biopharma companies developing large molecule therapeutics, coagulation/hematology products, plasma-derived therapies, and cell/gene therapies.

What Prolytix does

Prolytix is a privately held, U.S.-based bioanalytical Contract Research Organization (CRO) operating from Essex Junction, Vermont, focused exclusively on large molecule (biologics) drug development. Founded in 1987 as Haematologic Technologies by thrombosis and hemostasis scientist Kenneth Mann and rebranded to Prolytix in March 2022, the company provides assay development, validation, and release testing across protein therapeutics, coagulation and hematology therapies, plasma-derived products, and cell/gene therapies, operating in integrated GLP, GCP, CLIA, and GMP facilities certified to ISO 9001:2015. Its service portfolio spans PK/PD assays, immunogenicity (anti-drug antibody) testing, biomarker assays, GMP stability and release testing, host cell protein analysis using both ELISA and high-resolution mass spectrometry, and bioanalytical support for monoclonal antibodies, bispecifics, recombinant proteins, vaccines, and viral vectors.

The company monetizes primarily through statement-of-work-based CRO services billed at quoted per-project and hourly out-of-scope rates (Net 30 terms), supplemented by product revenue from a research-reagent catalog of 150+ blood coagulation products (plasma proteins, antibodies, deficient plasmas, custom IVD/POC reagents) and Custom Collection Devices (custom-formulated blood collection tubes) developed jointly with Greiner Bio-One. Reagent products are sold direct via the company's e-commerce storefront with bill-and-hold terms, while services engage via high-touch enterprise field sales with senior scientific staff embedded in client collaboration. Proprietary assets include the PROPath real-time project tracker, a mixed-mode HPLC method for polysorbate detection, a novel plasma fractionation technique for IgG, HRMS-based HCP workflows, and 60 validated thrombosis and hemostasis assays acquired from the Hemostasis Reference Laboratory in January 2026. The company sells primarily to biotech and biopharma developers of large molecule therapeutics, with >90% of new clients signing for a second project and 100% on-time delivery cited as core differentiators versus larger global CROs. Distribution and customer engagement are direct (phone, contact form, conference booths at ISTH/AAPS/ADLM/PPTA) with no channel partners or resellers.

The company has been PE-controlled since October 2019 under Edgewater Capital Partners, a Cleveland-based lower middle-market private equity firm focused on performance materials and life sciences. Governance includes CEO David Sunseri, Ph.D., COO Ryan Dorfman, Ph.D., and CFO Robert Weisman, with strategy centered on scaling the biologics CRO platform via organic capability expansion, bolt-on acquisitions (e.g., the HRL assay purchase, the Allumiqs multiomics partnership of March 2024), and entry into adjacent modalities such as cell and gene therapy and AI model validation.

Prolytix firmographics

Firmographics
Name
Prolytix
Legal name
Haematologic Technologies, LLC
Website
https://goprolytix.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
11–50 employees
Short description
Prolytix is a U.S.-based, PE-owned bioanalytical CRO providing GLP/GCP/CLIA/GMP-compliant assay development, validation, and release testing for biotech and biopharma companies developing large molecule therapeutics, coagulation/hematology products, plasma-derived therapies, and cell/gene therapies.
Ownership category
akta.pro rank

Prolytix industry classification

Industry
Product category
Bioanalytical Contract Research Services for Biopharmaceuticals
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Bioanalytical testing services
  • Contract research organization
  • Protein characterization services
  • GMP release testing
  • Host cell protein analysis

Where Prolytix is headquartered

Location

Headquarters

HQ city
Essex Junction
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Prolytix business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Bioanalytical CRO Services (Contract Research): Fee-for-service contract research organized by statement of work, quoted per project, billed at hourly rates for work outside standard scope. Services span GLP/GCP/CLIA/GMP assay development, validation, stability testing, release testing, and bioanalytical testing. Represents the core revenue stream.
  2. GMP Stability Testing & Storage: GMP-compliant stability testing and storage services for drug substance and drug product, supporting ICH-compliant programs and shelf-life determination.
  3. GMP Release Testing: GMP release testing for bulk, final product, and in-process materials with pre-defined release protocols.
  4. Research Reagent and Custom Product Sales: Sale of high-quality research reagents (plasma proteins, antibodies, inhibitors, substrates, deficient plasmas), custom IVD/POC reagents, and customized blood collection tubes. Subject to bill-and-hold arrangements. Courier expenses invoiced as pass-through plus 15%.
  5. Custom Collection Devices: Custom-designed and manufactured blood collection tubes and sample preservation devices for clinical trials and novel diagnostics, available in small pilot batches through large-scale GMP production.
  6. Critical Reagent Manufacturing: Manufacturing of custom critical reagents for biotherapeutic development programs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-Based Quoting (CRO Services)
OtherPay-as-you-goBill-and-Hold for Manufactured Materials
OtherMonthlyNet 30 Payment Terms

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Prolytix product offering

Product offering

Core offering

Prolytix is a bioanalytical Contract Research Organization that provides GLP, GCP, CLIA, and GMP compliant assay development, validation, stability testing, and release testing services for large molecule therapeutics including monoclonal antibodies, bispecifics, recombinant proteins, plasma-derived therapies, gene therapies, and vaccines. The company also manufactures and sells custom blood collection devices, critical reagents, and high-quality research reagents for biotech and biopharma clients.

Product overview

Prolytix is a bioanalytical Contract Research Organization (CRO) offering integrated services for large molecule biotherapeutic development. The portfolio includes drug modality-focused bioanalytical services (Coagulation & Hematology, Protein Based Therapeutics, Plasma-Derived Therapies, Food Allergens), regulatory-compliant testing services (GLP/GCP/CLIA/GMP), characterization and development services, proprietary PROPath project tracking software, and research reagent products. Solutions span Cell and Gene Therapies, Monoclonal & Polyclonal Antibodies, Vaccines and Viral Vectors, Recombinant Proteins, and Plasma-Based Proteins. Custom Collection Devices and Critical Reagent Manufacturing support clinical trials and diagnostic development. The company operates from 57 River Road in Essex Junction, VT, with over 35 years of protein chemistry expertise.

Differentiator

Problem solved

Functional benefit

Brands

  • PROPath: Real-time project tracker software for project management
  • Haematologic Technologies

Products and services

  • Coagulation & Hematology Bioanalytical Services Comprehensive bioanalytical testing services for hemophilia A and B, hemophilia C (Factor XI deficiency), von Willebrand Disease, direct oral anti-coagulants (DOACs), thrombin generation assays, platelet aggregation, and hemostatic risk evaluation for plasma-derived products, designed for biotech and biopharma developers of coagulation and hematology therapeutics.
  • Protein-Based Therapeutics Bioanalytical Services Bioanalytical assay development and validation services for monoclonal antibodies, bi- and tri-specific proteins, recombinant proteins, enzyme replacement therapies, and biosimilars, supporting biotech and biopharma developers of large molecule protein therapeutics from discovery through commercialization.
  • Plasma-Derived Therapies Bioanalytical Services Bioanalytical services for plasma fractionation and biotherapeutic development, including IVIG therapeutics, clotting factor analysis, and plasma protein characterization for plasma-derived therapy developers.
  • GLP, GCP & CLIA Services Regulatory-compliant bioanalytical testing services delivered under GLP, GCP, and CLIA frameworks, including pharmacokinetics assays, immunogenicity (anti-drug antibody) assays, biomarker assays, and hemostasis and coagulation assays and platforms.
  • GMP Services (Stability Testing & Release Testing) GMP-compliant stability testing and storage and release testing for bulk, final product, and in-process materials, supporting ICH-compliant programs and shelf-life determination for large molecule biopharmaceuticals.
  • Characterization & Development Services Method development, process development, protein characterization, and host cell protein analysis services for biotherapeutic development, leveraging high-resolution mass spectrometry (HRMS) alongside ELISA for comprehensive HCP identification and risk assessment.
  • PROPath Real-Time Project Tracker Proprietary real-time project management software that provides clients transparent access to project milestones, enabling faster decision-making and supporting highly effective program management with on-time delivery.
  • Analytical Validation of AI Models Service offering for analytical validation of AI models, bridging in silico predictions with empirical laboratory data for AI-driven biotech companies developing large molecule therapeutics.
  • Custom Collection Devices (CCD) Custom-designed and manufactured blood collection tubes and sample preservation devices for clinical trials and novel diagnostics, available in small pilot batches through large-scale GMP production via partnership with Greiner Bio-One.
  • Critical Reagent Manufacturing Manufacturing of custom critical reagents, including plasma proteins, antibodies, and custom IVD/POC device reagents for research and diagnostic applications.
  • High-Quality Research Reagents (Shop Products) Off-the-shelf and custom research reagents including coagulation proteins, antibodies, inhibitors, substrates, deficient plasmas, and custom IVD/POC reagents, sold directly through the Prolytix website storefront.

Quantifiable outcome

  • >90% of new clients sign for a second bioanalytical services project
  • +3 more outcomes

Companies that use Prolytix

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Prolytix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Prolytix partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • AllumiqscoreStrategic or Co-development Partner · 11 March 2024Long-term strategic partnership focused on delivering integrated solutions to help customers optimize drug development pipelines. Allumiqs brings multiomics and LC-MS/MS expertise in early R&D phases (mechanism of action, biomarker identification, drug product characteristics), while Prolytix provides complementary targeted method development for stability, potency, and GMP release testing. Together they offer interconnected solutions and blended expert teams, reducing risks and complications of transferring R&D work between vendors. The partnership was formalized after several successful joint customer engagements.
  • Greiner Bio-OnecoreStrategic or Co-development Partner · 20 August 2020Collaboration to provide end-to-end development and custom manufacturing of blood collection tubes for IVD and clinical diagnostic device developers. HTI (now Prolytix) contributes pilot-scale and small-to-medium batch customized blood collection tube production, while Greiner Bio-One contributes GMP-level high-volume batch manufacturing. The partnership creates a vertically integrated solution spanning early development to large-scale commercial production, enabling IVD developers to engage a single group rather than multiple vendors. HTI has sourced empty tubes and caps from Greiner Bio-One for many years prior to the formal collaboration.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Prolytix competitors and assessment

Company assessment

Direct peers

  • BioAgilytix Labs: BioAgilytix is a bioanalytical CRO specializing in large molecule biologics, immunoassays (PK, ADA, biomarker), and cell-based assays for biotech and pharma. Most directly comparable to Prolytix by therapeutic focus, assay types, and customer segment.
  • KCAS Bioanalytical: KCAS is a bioanalytical CRO focused on large molecule bioanalysis using LC-MS/MS, immunoassays, and biomarker services for biopharmaceutical clients. Similar size and modality mix, with overlapping capabilities in protein therapeutic characterization.
  • Celerion: Celerion is a clinical bioanalytical and early-phase CRO offering bioanalytical assay development, validation, and sample analysis for small and large molecules. Overlaps with Prolytix on regulated bioanalytical services for biopharma.
  • Frontage Laboratories: Frontage provides bioanalytical, CMC, and clinical laboratory services to biopharmaceutical companies, with significant large molecule bioanalysis and GMP release testing capabilities directly comparable to Prolytix's service portfolio.
  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO providing bioanalytical and clinical pharmacology services with strong capabilities in immunoassay and LC-MS/MS bioanalysis for biologics and complex therapeutics. Comparable in scale and scientific depth.

Broad incumbents

  • Charles River Laboratories: Charles River is a global, publicly-traded CRO offering bioanalytical, safety, and manufacturing services including large molecule and biologics support. Significantly larger than Prolytix and serves the same biotech/biopharma customer base with broader portfolio.
  • Labcorp Drug Development: Labcorp (including the former Covance) operates one of the largest global CRO and central lab networks, providing bioanalytical, biomarker, and clinical trial lab services. Competes with Prolytix for large molecule bioanalytical contracts from pharma/biotech.
  • IQVIA: IQVIA is the world's largest CRO with extensive bioanalytical laboratory capabilities supporting biologics and complex therapeutic development. Competes with Prolytix at the high end of large molecule bioanalytical services.
  • Eurofins Scientific: Eurofins operates a global network of bioanalytical and pharmaceutical testing laboratories, including specialty large molecule and biologics testing services. Overlaps with Prolytix across protein characterization, HCP, and release testing.
  • Thermo Fisher Scientific (PPD): Thermo Fisher's PPD clinical research business provides global bioanalytical and biologics testing services as part of its integrated CRO offering. Comparable to Prolytix in large molecule bioanalysis but operates at materially greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Prolytix compliance and trust

Trust signal

Compliance5 records

Prolytix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prolytix leadership team

Management profile

Number of profiles

Profiles5 records

Prolytix funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prolytix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prolytix

What does Prolytix do?

Prolytix is a bioanalytical Contract Research Organization that provides GLP, GCP, CLIA, and GMP compliant assay development, validation, stability testing, and release testing services for large molecule therapeutics including monoclonal antibodies, bispecifics, recombinant proteins, plasma-derived therapies, gene therapies, and vaccines. The company also manufactures and sells custom blood collection devices, critical reagents, and high-quality research reagents for biotech and biopharma clients.

Is Prolytix a public or private company?

Prolytix is a private company. It is classified as private equity controlled and is currently operating.

When was Prolytix founded?

Prolytix was founded in 1987. It employs 11 to 50 people.

Where is Prolytix based?

Prolytix is headquartered in Essex Junction, United States, in the North America region.

How does Prolytix make money?

Six revenue lines are on record. Bioanalytical CRO Services (Contract Research) is the primary driver. The others are GMP Stability Testing & Storage, GMP Release Testing, research Reagent and Custom Product Sales, custom Collection Devices and critical Reagent Manufacturing.

Who are Prolytix's main competitors?

Direct peers on record are BioAgilytix Labs, KCAS Bioanalytical, Celerion, Frontage Laboratories and Worldwide Clinical Trials. Broad incumbents are Charles River Laboratories, Labcorp Drug Development, IQVIA, Eurofins Scientific and Thermo Fisher Scientific (PPD).

Does Prolytix have an API?

No public API is recorded for Prolytix.

What industry is Prolytix in?

Prolytix's product category is Bioanalytical Contract Research Services for Biopharmaceuticals. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAGADAH, Cell-Based & Potency Assays (Bioassays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarVION Biosciences Expands Integrated Platform Across Biopharma Services and Diagnostic Workflow CapabilitiesVION Biosciences closed its acquisition of Prolytix, adding regulated bioanalytical and CMC services, diagnostic reagents, and sample collection products. The deal expands VION's large molecule testing and diagnostic workflow inputs, supporting translational, clinical, and commercial development. VION plans to integrate these capabilities into its operating model.BioSpaceRetham Technologies Launches Functional Cryopreserved Platelets for Research; Prolytix Named Distributor of Retham Cryoplatelets™Retham Technologies launched functional Cryoplatelets for research and named Prolytix as distributor. The product provides stable, on-demand platelets for assays, drug screening, and thrombin testing. It is available for research use only.Business Wire BlogRetham Technologies Launches Functional Cryopreserved Platelets for Research; Prolytix Named Distributor of Retham Cryoplatelets™Retham Technologies launched functional cryopreserved platelets for research and named Prolytix as distributor. The product addresses donor variability and logistical challenges, supporting assays, drug screening, and thrombin generation testing. It is available for research use only.Pulse 2.0Prolytix Acquires 60 HRL Assays To Expand Thrombosis And Hemostasis Testing ServicesProlytix acquired 60 validated assays from Hemostasis Reference Laboratory, expanding its thrombosis and hemostasis testing services. The acquisition combines Prolytix's protein science with HRL's coagulation expertise, and the company recently received a CLIA Certificate of Compliance with no deficiencies.MorningstarAllumiqs and Prolytix form strategic partnership to accelerate drug discovery and developmentAllumiqs and Prolytix announced a strategic partnership to accelerate drug discovery and development, combining Allumiqs' multiomics and LC-MS/MS expertise with Prolytix's large-molecule lifecycle management. The collaboration aims to reduce time-to-value and optimize R&D investments, covering early R&D through lot release.PR NewswireAllumiqs and Prolytix form strategic partnership to accelerate drug discovery and developmentAllumiqs and Prolytix announced a strategic partnership to deliver integrated bioanalytical solutions for drug development. The collaboration combines Allumiqs' LC-MS and multiomics expertise with Prolytix's large-molecule lifecycle services, aiming to reduce time-to-value and optimize R&D investments.BioSpaceHaematologic Technologies Is Now Prolytix, Integrating to Support Growing Large Molecule MarketHaematologic Technologies rebranded as Prolytix on March 1, 2022, integrating HT and Haemtech Biopharma Services. The company aims to support the growing large molecule bioanalytical testing market, which is projected to grow at a 9.5% CAGR until 2028.